Compass Pathways Highlights Phase 3 COMP360 TRD Gains, 26-Week Durability and FDA Path at Conference

Executives from Compass Pathways (NASDAQ:CMPS) discussed recent Phase 3 results for its COMP360 psilocybin program in treatment-resistant depression (TRD), highlighting statistically significant ...
Seeking Alpha

FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity

PLAINSBORO, N.J., May 2, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational ...

Glenmark Pharmaceuticals Inc. launches Milnacipran Hydrochloride Tablets

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg.
Blockonomi

Xenon Pharmaceuticals (XENE) Stock Rockets 40% on Breakthrough Epilepsy Trial Results

Xenon Pharmaceuticals (XENE) stock soared 40% after Phase 3 trial data for azetukalner exceeded expectations in focal onset seizures. FDA filing set for Q3 2026.